VIDEO: Momelotinib seems effective in anemic myelofibrosis
Click Here to Manage Email Alerts
CHICAGO — Aaron Thomas Gerds, MD, MS, of Cleveland Clinic Taussig Cancer Institute and Case Comprehensive Cancer Center, spoke with Healio about topline results from the MOMENTUM study presented at ASCO Annual Meeting.
The results showed that the spleen and symptom burden response rates were superior for momelotinib, a novel JAK1/2 and ACVR1/ALK2 inhibitor, compared with danazol in patients with myelofibrosis who were anemic and had prior JAK inhibitor exposure.
Gerds described momelotinib as “a one-for-all type of drug” because it can affect not only anemia, but also spleen size and symptoms.
“[The study] really showed that danazol was effective at transfusion-dependence rate — but turns out, momelotinib was better,” Gerds said in the video interview.
Collapse
Mesa RA, et al. Abstract 7002. Presented at: ASCO Annual Meeting; June 3-7, 2022; Chicago.
Read more about
Click Here to Manage Email Alerts